DaVita Inc. (NYSE:DVA) Shares Bought by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. lifted its position in shares of DaVita Inc. (NYSE:DVA - Free Report) by 7.9% during the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 55,255 shares of the company's stock after buying an additional 4,048 shares during the quarter. Envestnet Asset Management Inc. owned approximately 0.07% of DaVita worth $8,452,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. United Capital Financial Advisors LLC increased its position in shares of DaVita by 2.6% in the fourth quarter. United Capital Financial Advisors LLC now owns 2,416 shares of the company's stock valued at $361,000 after buying an additional 62 shares in the last quarter. Freedom Investment Management Inc. lifted its stake in shares of DaVita by 3.6% in the 4th quarter. Freedom Investment Management Inc. now owns 1,790 shares of the company's stock valued at $268,000 after purchasing an additional 62 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its stake in shares of DaVita by 2.0% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 3,551 shares of the company's stock valued at $531,000 after purchasing an additional 69 shares in the last quarter. UMB Bank n.a. raised its holdings in shares of DaVita by 65.5% during the 1st quarter. UMB Bank n.a. now owns 192 shares of the company's stock valued at $29,000 after buying an additional 76 shares during the period. Finally, Exchange Traded Concepts LLC raised its holdings in shares of DaVita by 8.9% during the 1st quarter. Exchange Traded Concepts LLC now owns 970 shares of the company's stock valued at $148,000 after buying an additional 79 shares during the period. 90.12% of the stock is owned by hedge funds and other institutional investors.

DaVita Price Performance

Shares of DaVita stock traded up $6.66 during trading hours on Tuesday, reaching $146.09. The company's stock had a trading volume of 970,731 shares, compared to its average volume of 810,769. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.25 and a quick ratio of 1.20. The stock has a market cap of $11.03 billion, a P/E ratio of 14.48, a P/E/G ratio of 0.97 and a beta of 1.11. The firm has a 50 day moving average price of $140.11 and a 200-day moving average price of $148.56. DaVita Inc. has a one year low of $131.76 and a one year high of $179.60.

DaVita (NYSE:DVA - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported $2.00 earnings per share for the quarter, beating analysts' consensus estimates of $1.75 by $0.25. The business had revenue of $3.22 billion during the quarter, compared to analysts' expectations of $3.22 billion. DaVita had a net margin of 6.63% and a return on equity of 176.11%. The business's revenue for the quarter was up 5.0% on a year-over-year basis. During the same period last year, the business earned $2.26 earnings per share. On average, analysts predict that DaVita Inc. will post 10.76 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. Truist Financial reduced their price target on DaVita from $170.00 to $164.00 and set a "hold" rating for the company in a research report on Monday, May 19th. Wall Street Zen raised DaVita from a "hold" rating to a "buy" rating in a report on Friday, April 25th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $164.50.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.